Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Metrics to compare | FOLD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipFOLDPeersSector | |
---|---|---|---|---|
P/E Ratio | −31.4x | −4.4x | −0.6x | |
PEG Ratio | −0.75 | −0.05 | 0.00 | |
Price/Book | 18.4x | 2.8x | 2.6x | |
Price / LTM Sales | 6.7x | 8.2x | 3.2x | |
Upside (Analyst Target) | 59.2% | 75.6% | 44.1% | |
Fair Value Upside | Unlock | 2.2% | 6.2% | Unlock |